Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease.
EORTC QLQ-C30
EQ-5D-5L
FACT-BMT
graft-versus-host disease
health-related quality of life
patient-reported outcomes
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
20
04
2023
received:
25
01
2023
accepted:
21
04
2023
medline:
19
7
2023
pubmed:
4
5
2023
entrez:
3
5
2023
Statut:
ppublish
Résumé
Evidence regarding health-related quality of life (HRQoL) in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD) is lacking. Evaluating HRQoL was a secondary objective of the HOVON 113 MSC trial. Here we describe the outcomes of the EQ-5D-5L, EORTC QLQ-C30, and FACT-BMT for all adult patients who completed these questionnaires at baseline (i.e., before the start of treatment; n = 26). Descriptive statistics were used to describe baseline patient and disease characteristics, EQ-5D dimension scores and values, EQ VAS scores, EORTC QLQ-C30 scale/item and summary scores, and FACT-BMT subscale and total scores. The mean EQ-5D value was 0.36. In total, 96% of the patients reported problems with usual activities, 92% with pain/discomfort, 84% with mobility, 80% with self-care, and 72% with anxiety/depression. The mean EORTC QLQ-C30 summary score was 43.50. Mean scale/item scores ranged from 21.79 to 60.00 for functioning scales, from 39.74 to 75.21 for symptom scales, and from 5.33 to 91.67 for single items. The mean FACT-BMT total score was 75.31. Mean subscale scores ranged from 10.09 for physical well-being to 23.94 for social/family well-being. Our study showed that HRQoL in patients with SR-aGvHD is poor. Improving HRQoL and symptom management in these patients should be a top priority.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence regarding health-related quality of life (HRQoL) in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD) is lacking. Evaluating HRQoL was a secondary objective of the HOVON 113 MSC trial. Here we describe the outcomes of the EQ-5D-5L, EORTC QLQ-C30, and FACT-BMT for all adult patients who completed these questionnaires at baseline (i.e., before the start of treatment; n = 26).
METHODS
METHODS
Descriptive statistics were used to describe baseline patient and disease characteristics, EQ-5D dimension scores and values, EQ VAS scores, EORTC QLQ-C30 scale/item and summary scores, and FACT-BMT subscale and total scores.
RESULTS
RESULTS
The mean EQ-5D value was 0.36. In total, 96% of the patients reported problems with usual activities, 92% with pain/discomfort, 84% with mobility, 80% with self-care, and 72% with anxiety/depression. The mean EORTC QLQ-C30 summary score was 43.50. Mean scale/item scores ranged from 21.79 to 60.00 for functioning scales, from 39.74 to 75.21 for symptom scales, and from 5.33 to 91.67 for single items. The mean FACT-BMT total score was 75.31. Mean subscale scores ranged from 10.09 for physical well-being to 23.94 for social/family well-being.
CONCLUSION
CONCLUSIONS
Our study showed that HRQoL in patients with SR-aGvHD is poor. Improving HRQoL and symptom management in these patients should be a top priority.
Substances chimiques
Steroids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-246Subventions
Organisme : European Union's Horizon 2020 research and innovation program
ID : 643580
Organisme : Dutch Cancer Society
Informations de copyright
© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Zeiser R, Blazar BR. Acute graft-versus-host disease: biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167-2179. doi:10.1056/NEJMra1609337
Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer. 2004;101(9):1936-1946. doi:10.1002/cncr.20613
MacMillan ML, Robin M, Harris AC, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21(4):761-767. doi:10.1016/j.bbmt.2015.01.001
Westin JR, Saliba RM, De Lima M, et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol. 2011;2011:e601953. doi:10.1155/2011/601953
Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163. doi:10.1016/j.bbmt.2012.04.005
Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34(5):1229-1240. doi:10.1038/s41375-020-0804-2
Martin PJ. How I treat steroid-refractory acute graft-versus-host disease. Blood. 2020;135(19):1630-1638. doi:10.1182/blood.2019000960
Patel SS, Lapin B, Majhail NS, Hamilton BK. Patient-reported outcomes in acute graft-versus-host disease: optimizing patient care and clinical trial endpoints. Bone Marrow Transplant. 2020;55(8):1533-1539. doi:10.1038/s41409-020-0850-4
Kilgour JM, Wali G, Gibbons E, et al. Systematic review of patient-reported outcome measures in graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(5):e113-e127. doi:10.1016/j.bbmt.2020.01.022
Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication. A randomized controlled trial. JAMA. 2002;288(23):3027-3034. doi:10.1001/jama.288.23.3027
HOVON. HOVON 113 MSC. Accessed November 25, 2021. https://hovon.nl/en/trials/ho113
EU Clinical Trials Register. Protocol HO113. Accessed September 5, 2022. https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004915-30/BE
CORDIS EU. Restoring tissue regeneration in patients with visceral graft versus host disease. Accessed September 5, 2022. https://cordis.europa.eu/project/id/643580
Devlin N, Parkin D, Janssen B. Methods for Analysing and Reporting EQ-5D Data. Springer; 2020.
EORTC. EORTC QLQ-C30 Scoring Manual; 2001. Accessed December 22, 2021. https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf
FACIT. FACT-BMT. Accessed December 22, 2021. https://www.facit.org/measures/FACT-BMT
van Wilder L, Charafeddine R, Beutels P, et al. Belgian population norms for the EQ-5D-5L, 2018. Qual Life Res. 2022;31(2):527-537. doi:10.1007/s11136-021-02971-6
Grochtdreis T, Dams J, König HH, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20(6):933-944. doi:10.1007/s10198-019-01054-1
Garcia-Gordillo MA, Adsuar JC, Olivares PR. Normative values of EQ-5D-5L: in a Spanish representative population sample from Spanish Health Survey, 2011. Qual Life Res. 2016;25(5):1313-1321. doi:10.1007/s11136-015-1164-7
Versteegh MM, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19(4):343-352. doi:10.1016/j.jval.2016.01.003
EORTC. Scoring of the QLQ-C30 Summary Score; 2018. Accessed December 22, 2021. https://qol.eortc.org/app/uploads/sites/2/2018/02/scoring_of_the_qlq-c30_summary_score.pdf
Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79-88. doi:10.1016/j.jclinepi.2015.08.007
StataCorp. Stata Statistical Software. StataCorp; 2019.
Luckett T, King MT, Butow PN, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011;22(10):2179-2190. doi:10.1093/annonc/mdq721
Kopp M, Schweigkofler H, Holzner B, et al. EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparison. Eur J Haematol. 2000;65(2):97-103. doi:10.1034/j.1600-0609.2000.90143.x
Nolte S, Liegl G, Petersen MA, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer. 2019;107:153-163. doi:10.1016/j.ejca.2018.11.024
Golicki D, Jaśkowiak K, Wójcik A, et al. EQ-5D-derived health state utility values in hematologic malignancies: a catalog of 796 utilities based on a systematic review. Value Health. 2020;23(7):953-968. doi:10.1016/j.jval.2020.04.1825
Kurosawa S, Yamaguchi T, Mori T, et al. Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. Bone Marrow Transplant. 2015;50(9):1241-1249. doi:10.1038/bmt.2015.137